NCT04884906 is a Phase 2 clinical trial of Camrelizumab in Locally Advanced Cervical Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT04884906?

NCT04884906 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04884906?

Interventions in NCT04884906: Camrelizumab, radiotherapy, Albumin Paclitaxel, Cisplatin.

What condition does NCT04884906 study?

NCT04884906 studies Locally Advanced Cervical Cancer.

Is NCT04884906 still recruiting?

NCT04884906 is currently status unknown. Last updated 13 May 2021.

Last reviewed 2021-05-13 · How we verify

NCT04884906

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Status unknown Phase 2 Last updated 13 May 2021

What this trial tests

Phase 2 trial testing Camrelizumab in Locally Advanced Cervical Cancer in 40 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
1 November 2022

1 November 2024

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 November 2020
Primary completion	1 November 2022
Estimated completion	1 November 2024
Sites	1 location across China

Drugs / interventions tested

Camrelizumab — full drug profile →
radiotherapy — full drug profile →
Albumin Paclitaxel — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Locally Advanced Cervical Cancer — all drugs for Locally Advanced Cervical Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Locally Advanced Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Targeting immune microenvironment in cervical cancer: current research and advances.
Zhang Z, Liu M, An Y, Gao C, et al · · 2025 · cited 6× · PMID 40781691 · DOI 10.1186/s12967-025-06896-3
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Locally Advanced Cervical Cancer

Currently open trials in the same condition.

NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
NCT07055399 — Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) · Phase 2 · recruiting
NCT06943833 — A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) · Phase 2 · active not recruiting
NCT07205497 — QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer · Phase 2 · active not recruiting
NCT07104149 — Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer · Phase 2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04884906 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 13 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04884906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing